EGFR and glioblastoma: Together, these database analyses predict that, despite high levels of EGFR genetic alteration observed in GBM, the lack of kinase-activating mutations and lack of impact of EGFR alteration on the tumour immune microenvironment suggest that EGFR kinase inhibitors are likely to have differing efficacy in EGFR mutant NSCLC and GBM.